Bao L.T. Tran

By An V. Tran, Diem T. Nguyen, Son K. Tran, Trang H. Vo, Kien T. Nguyen, Phuong M. Nguyen, Suol T. Pham, Chu X. Duong, Bao L.T. Tran, Lien N.T. Tran, Han G. Diep, Minh V. Huynh, Thao H. Nguyen, Katja Taxis, Khanh D. Dang and Thang Nguyen

Coronary artery disease (CAD) remains the leading cause of mortality among cardiovascular diseases, responsible for 16% of the world’s total deaths. According to a statistical report published in 2020, the global prevalence of CAD was estimated at 1655 per 100,000 people and is predicted to exceed 1845 by 2030. Annually, in the United States, CAD accounts for approximately 610,000 deaths and costs more than 200 billion dollars for healthcare services. Most patients with CAD need to be treated over long periods with a combination of drugs. Therefore, the inappropriate use of drugs, or drug-related problems (DRPs), can lead to many consequences that affect these patients’ health, including decreased quality of life, increased hospitalization rates, prolonged hospital stays, increased overall health care costs, and even increased risk of morbidity and mortality. DRPs are common in CAD patients, with a prevalence of over 60%. DRPs must therefore be noticed and recognized by healthcare professionals. This chapter describes common types and determinants of DRPs in CAD patients and recommends interventions to limit their prevalence.

Part of the book: Coronary Artery Bypass Grafting